Recent advancements in genome editing techniques, namely CRISPR/Cas9, have greatly facilitated cell line engineering, gene targeting, and the development of transgenic models. However, identification of correctly targeted cells remains a significant bottleneck for large-scale projects.
To remove this hurdle, GENEWIZ developed genoTYPER-NEXT™, a proprietary NGS-based assay ideal for ultra-sensitive, high-throughput, sample-to-answer genotyping projects. This tool is more effective and efficient than T7E1, TIDE, and IDAA assays for screening targeted cell lines.
We also offer targeted, whole genome, and amplicon sequencing NGS solutions to aid on- and off-target analysis of genome editing.
Submit CRISPR-edited cell lines in 96-well plates
Cells lysis and PCR with barcoded primers
Samples pooled and sequenced on Illumina® platform
Visualize results in genoTYPER-NEXT browser
.ashx?la=en-GB&hash=D9F4022339F96D733DB07C4E7E58B8491F0A94C8)
Discover the powerful capabilities of genoTYPER-NEXT in this illuminating case study and learn how this high-throughput assay allows rapid and accurate genotyping of CRISPR-edited cell lines.
.ashx?la=en-GB&hash=EC360D5F8792D71715D8925EA7FB49FDA4A40555)
This selection guide offers practical information about PCR + Sanger, qPCR, and NGS approaches to help you determine which assay best suits your project requirements, along with an interactive assay selection tool to aid your decision making.
US
Europe (English)
Chinese
Japanese
